Tcr2 Therapeutics Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
100 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 384 % -73%
Debt-to-equity 41 % +154%
Return On Equity -97.8 % -167%
Return On Assets -69.4 % -120%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.2M shares +1.81%
Common Stock, Shares, Outstanding 39.2M shares +1.81%
Entity Public Float 89.6B USD -81.8%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.2M shares +1.84%
Weighted Average Number of Shares Outstanding, Diluted 39.2M shares +1.84%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 106M USD +32%
General and Administrative Expense 26.3M USD +13.7%
Operating Income (Loss) -166M USD -54.4%
Nonoperating Income (Expense) 2.93M USD +1203%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -163M USD -52%
Income Tax Expense (Benefit) 228K USD -21.1%
Net Income (Loss) Attributable to Parent -163M USD -51.8%
Earnings Per Share, Basic -4.2 USD/shares -35.5%
Earnings Per Share, Diluted -4.2 USD/shares -35.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.4M USD -80.5%
Assets, Current 140M USD -43.2%
Property, Plant and Equipment, Net 3.34M USD -82.2%
Operating Lease, Right-of-Use Asset 5.81M USD -89.5%
Other Assets, Noncurrent 717K USD -9.36%
Assets 152M USD -53.1%
Accounts Payable, Current 6.32M USD +41%
Employee-related Liabilities, Current 2.3M USD +17.3%
Accrued Liabilities, Current 9.22M USD -2.49%
Liabilities, Current 47.5M USD +53.8%
Operating Lease, Liability, Noncurrent 2.71M USD -92.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 50.2M USD -26.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -188K USD +45.3%
Retained Earnings (Accumulated Deficit) -542M USD -43.1%
Stockholders' Equity Attributable to Parent 101M USD -60.3%
Liabilities and Equity 152M USD -53.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40M USD -28.5%
Net Cash Provided by (Used in) Investing Activities 21.7M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 39.2M shares +1.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3M USD +87.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.6M USD -79.3%
Deferred Tax Assets, Valuation Allowance 125M USD +61.3%
Deferred Tax Assets, Gross 131M USD +53.6%
Operating Lease, Liability 5.98M USD -88.9%
Depreciation 500K USD -16.7%
Payments to Acquire Property, Plant, and Equipment 158K USD -91.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -163M USD -51.3%
Lessee, Operating Lease, Liability, to be Paid 6.66M USD -93.2%
Property, Plant and Equipment, Gross 8.18M USD -65.3%
Operating Lease, Liability, Current 3.27M USD -80.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.54M USD -60%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.07M USD -88.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure -13.7%
Deferred Income Tax Expense (Benefit) 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 680K USD -98.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.05M USD -79.9%
Deferred Tax Assets, Operating Loss Carryforwards 79.5M USD +33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.33M USD -17.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 615K USD -12.9%
Share-based Payment Arrangement, Expense 8.78M USD -28.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%